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Abstract: Docosahexaenoic acid (DHA), a major polyunsaturated fatty acid (PUFA) in the phospholipid frac-
tion of the brain, is essential for normal cellular function. Neurodegenerative disorders such as Parkinson’s
disease (PD) often exhibit significant declines in PUFAs. The aim of this study was to observe the effects of
DHA supplementation in an experimental rat model of PD created with ‘1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine’ (MPTP). Adult male Wistar rats were divided into four groups: (1) Control; (2) DHA-treated; (3)
MPTP-induced; and (4) MPTP-induced + DHA-treated. Motor activity was investigated using the ‘vertical
pole’ and ‘vertical wire’ tests. The dopaminergic lesion was determined by immunohistochemical analysis for
tyrosine hydroxylase (TH)-immunopositive cells in substantia nigra (SN). Immunoreactivities of Bcl-2, Akt and
phosphorylated-Akt (p-Akt) in SN were evaluated by immunohistochemistry. MPTP-induced animals exhibited
decreased locomotor activity, motor coordination and loss of equilibrium. Diminished Parkinsonism symptoms
and decreased dopaminergic neuron death were detected in the MPTP-induced + DHA-treated group com-
pared to the MPTP-induced group. Moderate decreases in Akt staining were found in the MPTP-induced and
MPTP-induced + DHA-treated groups compared to controls. p-Akt immunoreactivity decreased dramatically
in the MPTP-induced group compared to the control; however, it was increased in the MPTP-induced + DHA-
-treated group compared to the MPTP-induced group. The staining intensity for Bcl-2 decreased prominently in
the MPTP-induced group compared to the control, while it was stronger in the MPTP-induced + DHA-treated
group compared to the MPTP-induced group. In conclusion, DHA significantly protects dopaminergic neurons
against cell death in an experimental PD model. Akt/p-Akt and Bcl-2 pathways are related to this protective
effect of DHA in experimental PD. (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 2, 228–238)
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Introduction
Docosahexaenoic acid (DHA) is the major polyunsatu-
rated fatty acid (PUFA) in the phospholipid fractions of
the brain and is required for normal cellular function
[1, 2]. The maintenance of adequate concentrations of
this PUFA is essential for cognition, learning and memo-
ry [2–4]. However, with aging, membrane PUFA concen-
trations decline, leading to cognitive impairment. It is
evident that there is a significant decline in DHA and
other PUFAs in neurodegenerative disorders such as
Parkinsonism and Alzheimer’s disease [2]. Supplemen-
tation of these PUFAs may help delay the onset of such
diseases or may reduce the insult to brain functions [2, 5].
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Parkinson’s disease (PD) is triggered by certain
predisposing factors including environmental factors,
free radicals, oxidative stress, mitochondrial dysfunc-
tion, excitotoxicity, calcium cytotoxicity, trophic fac-
tor deficiency, inflammatory processes, genetic fac-
tors and/or undefined insults, resulting in a progres-
sive loss of dopaminergic neurons in the nigrostri-
atal pathway [6–8]. The loss of dopaminergic
afferents to the striatum and putamen results in ex-
tra-pyramidal motor dysfunction, including tremor,
rigidity and bradykinesia [6, 7]. Although other neu-
rotransmitter systems are affected in this condition,
dopamine (DA) depletion is the major neurochem-
ical alteration [9]. The exact cause of this neuronal
loss is still unknown, but recent human post mor-
tem studies have suggested that, in PD, nigral
dopaminergic neurons die by apoptosis [10] as do
dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-
-tetrahydropyridine (MPTP)-treated rodents [10, 11],
an in vivo model of PD.
MPTP has been used in animal models to investi-
gate the process of neurodegeneration with the aim
of developing antioxidant neuroprotective drugs.
MPTP is a potent neurotoxin that selectively destroys
the nigrostriatal dopaminergic neurons in humans,
sub-human primates, and lower animals [12–14].
MPTP is a highly lipophilic compound and can cross
the blood brain barrier [15]. MPTP itself is not toxic.
Inside the brain, the pro-toxin MPTP is rapidly me-
tabolized into the toxic cation 1-methyl-4-phenylpy-
ridinium (MPP+) the active neurotoxin, by monoam-
ine oxidase B (MAO-B) in glial cells. Furthermore,
MPP+ is selectively accumulated in dopaminergic
neurons where it interferes with the mitochondrial
metabolism via inhibiting the electron transport chain,
decreasing mitochondrial membrane potential, and
inducing disturbances in Ca2+ homeostasis, which
could eventually lead to cell death and the build-up
of free radicals, toxic molecules that contribute fur-
ther to neuronal cell destruction [16–19].
Dietary fish oils rich in DHA may offer a protec-
tive role against neuron death seen in PD. However,
the underlying mechanisms are not well understood.
Supporting a role for DHA in neuroprotection,
a study has shown that DHA promotes neuronal sur-
vival by facilitating membrane translocation/activa-
tion of Akt, a downstream effector in the phosphoi-
nositide 3-kinase (PI3K) pathway, and in vivo reduc-
tion of DHA by dietary depletion increased hippoc-
ampal neuronal susceptibility to apoptosis [20]. It has
been shown that pharmacological inhibition of PI3K
blocks the cell survival effect of DHA, and enrich-
ment of cells with DHA partially rescues the phos-
phorylation and activity of the protein kinase Akt in
the absence of serum [20].
Because there are multiple downstream effectors
of Akt, it is not completely clear how the survival sig-
nal is transduced. One possibility is that the PI3K/Akt
signaling pathway might act through modulation of Bcl-2
expression, and it has been shown that expression of
Bcl-2 is induced by a-synuclein [21]. Supporting this
possibility, several studies have demonstrated that ac-
tivated Akt stimulated changes in Bcl-2 and Bax ex-
pression and showed anti-apoptotic effects in many dif-
ferent cell types, including hippocampal neurons and
PC12 cells [22, 23]. Acting via the Akt signaling path-
way, DHA might increase Bcl-2 expression in neuronal
cell membranes, thereby protecting against apoptosis.
Currently, drug therapy cannot completely cure
PD. However Youdim et al. demonstrated that chronic
treatment with a low dose of rasagiline (N-propar-
gyl-1-(R)-aminoindan) which is a highly potent irre-
versible MAO-B inhibitor, increased DA in the rat
striatum [24]. Furthermore it has been demonstrated
that Parkinsonian subjects respond to low doses of
rasagiline, (0.5–2 mg daily) in controlled monothera-
py and adjunct L-Dopa therapy, as shown in early
and late PD studies [25–27]. Nonetheless, efforts are
still being made to investigate new drugs with both anti-
parkinsonian and neuroprotective effects. In this con-
text, the main objective of the present study was to in-
vestigate some of the signaling proteins involved in the
mechanisms of DHA neuroprotection observed in ex-
perimental PD.
Material and methods
Animals. Adult male Wistar rats (12 months old, weighing
375–425 g) were obtained from Akdeniz University Animal
Research Unit. The animals were housed in stainless steel
cages (4–5 per cage) in an air-conditioned room (22°C with
a 12 hour light:12 hour dark cycle) with food and water avail-
able ad libitum. All experimental protocols conducted on
rats were performed in accordance with the standards es-
tablished by the Institutional Animal Care and Use Com-
mittee at Akdeniz University Medical School.
Experimental design. Rats were randomly divided into four
experimental groups as follows: (1) control; (2) DHA-treat-
ed; (3) MPTP-induced; (4) MPTP-induced + DHA-treat-
ed. DHA (Sigma–Aldrich, St. Louis, MO, USA) was dis-
solved in corn oil at a concentration of 0.046 M and was
given to the treatment groups for 30 days (36 mg/kg/day) by
gavage [28–33]. In order to eliminate the effects of daily
gavage and vehicle, the control and MPTP-induced rats re-
ceived a similar volume of corn oil alone.
Surgery. On the 23rd day of gavage treatment, MPTP-induced
and MPTP-induced + DHA-treated animals were anesthe-
tized with 400 mg/kg chloral hydrate intraperitoneally (i.p.).
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MPTP (100 µg in 1 µl saline) was infused bilaterally into the
medial forebrain bundle (MFB) using a Hamilton micro-sy-
ringe at a rate of 0.33µl/min [34], according to the following
coordinates adapted from the Pellegrino [35]: anteroposterior
(AP) — 2.2 mm from the bregma; mediolateral (ML) ± 1.5
mm from midline; and dorsoventral (DV) — 8.0 mm from the
skull. After surgery, the animals were allowed to recover from
anesthesia in a temperature-controlled chamber and then
placed in individual cages. All four animal groups continued
on their normal diets for an additional week after surgery.
Tests of motor activity. Seven days after the creation of the
experimental PD model, motor activity of the rats was in-
vestigated using the ‘vertical pole’ and ‘vertical wire’ tests.
The results of these tests confirmed that the created model
of PD was reliable [36, 37].
For the vertical pole test, the animal was placed face up
on a cloth-tape-covered pole (3.0 cm diameter, 150 cm
length), which was held in a horizontal position, then the
pole was gradually lifted to a vertical position and the time
a rat stayed on the pole was recorded for a maximum of 120 s.
In this test, an animal with deficits in motor coordination
and balance will fall off the pole [36].
We also analyzed the rat catalepsy state on vertical wire
netting (size 56.5 × 23.5 cm; mesh 1 × 1 cm; wire diameter
2 mm). The rats were placed with all paws on the wire net
and the time taken for at least one paw to be actively dis-
placed from the bar (descent latency) was determined [37].
Tissue collection. At the end of the treatment period,
rats were anesthetized with a combination of ketamine
(80 mg/kg, i.p.) and xylazine (15 mg/kg, i.p.), perfused tran-
scardially with heparinized saline and their brains were re-
moved immediately. For immunohistochemical studies,
brain tissues containing SN were fixed in 4% formaldehyde
for 8 h and washed with tap water for approximately 6 h
afterwards; brain tissues were dehydrated in ethanol and
embedded in paraffin for immunohistochemical stainings.
5-µm thick sections were collected onto poly-l-lysine-coat-
ed slides (Sigma–Aldrich, St. Louis, MO, USA).
Immunohistochemistry. For tyrosine hydroxylase (TH), Akt,
p-Akt and Bcl-2 immunohistochemistry, paraffin sections
were deparaffinized in xylene and rehydrated in a graded
series of ethanol. Sections were immersed in 3% hydrogen
peroxide in methanol for 15 min to block endogenous per-
oxidase activity. Slides were then incubated with universal
blocking reagent (BioGenex, San Ramon, CA, USA) for 10
min at room temperature. Afterwards, excess serum was
drained and sections were incubated with primary antibod-
ies mouse monoclonal anti-TH (1/100; Calbiochem, CA,
USA; #657010), rabbit polyclonal Akt (1/50; Cell signal-
ling; #9272), rabbit polyclonal p-Akt (1/50; Cell signaling;
#9275) and rabbit polyclonal anti-Bcl-2 (1/600; Abcam plc.,
Cambridge, UK; ab7973) in a humidified chamber for 2 h
at room temperature. For negative controls, the primary
antibodies were replaced by normal rabbit IgG serum (Vec-
tor Labs., Burlingame, CA, USA) at the same concentra-
tion. After several washes in PBS, sections were incubated
with biotinylated polyvalent secondary antibody (K0675;
LSAB2 System-HRP; DakoCytomation, Glostrup, Den-
mark) for 30 min followed by LSAB streptavidin-peroxi-
dase complex (Dako, Carpinteria, CA, USA) incubation for
30 min and were rinsed with PBS. Antibody complexes were
visualized by incubation with diaminobenzidine (DAB) chro-
mogen (BioGenex). Sections were counterstained with
Mayer’s hematoxylin (Dako), dehydrated, mounted and
examined by an Axioplan microscope (Zeiss, Oberkochen,
Germany). The images were taken using a 5MP Canon A95
camera integrated to the microscope.
Evaluation of Tyrosine Hydroxylase (TH)-positive neurons.
TH-positive neuron numbers were assessed to confirm the
accuracy of the MPTP-induced experimental PD model at the
histological level. To assay changes in the number of dopamin-
ergic neurons in the SN, the total numbers of TH-stained neu-
rons were counted independently by two observers blinded to
the type and source of the tissues under a light microscope
(40 × magnification) in six slides from each of the groups. The
average of counts was used (data not shown) [33].
Measurement of densitometrical staining intensities. The
densitometrical staining intensities of the Akt, p-Akt and
Bcl-2 in SN of animals were measured by values of immun-
ostaining. Densitometric measurements were performed in
six different regions of SN sections. Immunostaining inten-
sities were presented as the mean of measured layer value
minus mean of measured background value. Morphomet-
ric analysis was performed with a Zeiss Axioscop-2 Plus mi-
croscope at 20 × magnification coupled with Image System
Analysis, Axiovision Ver. 4.7 (Carl Zeiss, Jena, Germany).
Results
Motor activity
According to the motor activity tests, a significant de-
crease in motor activity was found in the MPTP-in-
duced groups compared to the control and DHA-treat-
ed groups. Moreover, the motor activity was signifi-
cantly improved in the MPTP induced + DHA-treat-
ed group when compared to the MPTP-induced group,
but did not reach control levels (data not shown).
Quantitative analysis of Tyrosine Hydroxylase
(TH) Positive cell in the Substantia Nigra (SN)
The compact, reticular and lateral parts of the rat SN
were easily distinguished by TH immunohistochem-
istry. The immunoreactivity for TH was observed in
231The effects of DHA in a rat model of Parkinson’s disease
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2012
10.5603/FHC.2012.0032
www.fhc.viamedica.pl
neuron bodies and processes. No immunoreactivity was
observed in glial cells or the endothelium (Figure 1).
The TH-immunoreactive neuron numbers in the
SN of the control, MPTP-induced, DHA-treated, and
MPTP-induced + DHA-treated groups were counted
by two observers. According to these counts, the dopam-
inergic neuron numbers in the MPTP-induced group
were significantly lower compared to all the other groups
(data not shown) which confirmed that the model of
PD was achieved successfully. Moreover, the dopamin-
ergic neuron numbers significantly increased in the
MPTP-induced + DHA-treated group when compared
to the MPTP-induced group (data not shown).
Dopaminergic neuron processes of the MPTP-in-
duced group were found to be sparse and disorga-
nized compared to the other groups. In the MPTP-
-induced + DHA-treated group, the neuron processes
were more organized compared to the MPTP-induced
group. No staining was observed in the negative
sections (Figure 1).
Immunoreactivity of Akt and p-Akt
in the Substantia Nigra (SN)
Immunohistochemical analysis showed that Akt im-
munoreactivity intensity was strong in the control
(995) and DHA-treated (1,041.93) groups, while it was
found to be decreased in the MPTP-induced (876.94)
and MPTP-induced + DHA-treated (882.63) groups
(Figure 2). In addition, there was very weak p-Akt im-
munoreactivity in the MPTP-induced group (790.11).
On the other hand, p-Akt revealed a moderate immu-
nostaining in the MPTP-induced + DHA-treated
group (1,129.74) while it exerted a strong immunore-
activity in the control (1,602.32) and DHA-treated
(1,590.74) groups (Figure 3). No immunoreactivity was
observed on the slides where primary antibodies were
replaced with normal rabbit IgG (data not shown).
Immunoreactivity of Bcl-2
in the Substantia Nigra (SN)
Bcl-2 protein was mainly localized to SN dopaminer-
gic neuron bodies, and to a lesser extent to their pro-
cesses. The staining intensity for Bcl-2 in the MPTP-
-induced group was weak (934.49) while it was mod-
erate (1,045.82) in the MPTP-induced + DHA-treat-
ed group. A strong immunoreactivity was observed
in the control (1,237.07) and DHA-treated (1,080.92)
groups (Figure 4).
Discussion
In the present study, we have demonstrated that DHA
treatment can alleviate MPTP induced nigrostriatal
dopaminergic neuron degeneration and motor im-
pairments in adult rats. Moreover, our findings indi-
cate that the beneficial effect of DHA treatment on
experimental PD was associated with the induction
of prosurvival molecules such as Akt and Bcl-2.
In our study, neurotoxin MPTP was infused bilat-
erally into the MFB. Historically, MFB lesion model
is the most widely used [34, 38, 39]. Because the
dopaminergic axons of the mesolimbocortical path-
way also transverse the MFB, this meant that inject-
ing MPTP at this site also lesioned the ventral teg-
mental cell bodies and their terminals in the forebrain.
The dopaminergic neuron numbers in the MPTP-in-
duced group were significantly lower compared to all
other groups [33]. There was a ~70% decline in TH
immunopositive neurons in SN by one week after in-
jection of MPTP into MFB, in agreement with previ-
ous reports [40–43]. MPTP caused damage to nigral
dopaminergic neurons as seen in PD [44, 45]. The
dopaminergic neuron numbers significantly increased
in the MPTP-induced + DHA-treated group com-
pared to the MPTP-induced group [33]. This indicates
a relationship between TH positive neuron number
depletion and diminished Parkinsonism symptoms
that were detected in the DHA supplemented MPTP
group. Our TH immunohistochemistry results have
shown that DHA may partially restore dopaminergic
neuron numbers in this model of PD. Previous stud-
ies have suggested that a high n-3 PUFA diet pre-
vents the MPTP-induced decrease of a TH-labeled
nigral cell [46, 47].
In the present study, the DHA dose was selected
according to previous studies [28–33]. Daily intake of
DHA was used with different doses in different ex-
perimental studies. Low DHA concentrations were
found to be effective as a therapeutic agent, since high
doses were cytotoxic to both normal and pathologic
cells [48].
Degeneration of nigrostriatal structures was asso-
ciated with motor dysfunction while bilateral lesions
in the nigrostriatal system produce akinesia, rigidity
and catalepsy [49]. There was a high degree of corre-
lation between dopaminergic neuron degeneration
and motor impairment in MPTP-induced Parkin-
sonism model [49]. Measurement of motor activity in
experimental Parkinsonism models depends on the
performance of animals in well defined tasks. We have
performed these tests to confirm that the created
model of PD was reliable [33]. MPTP-administered
rats displayed typical behavioral characteristics of PD
in the vertical pole and catalepsy tests [33]. These find-
ings were in agreement with results from previous
studies which demonstrated the impairment of mo-
tor activity in MPTP-induced Parkinsonism models
[50–54]. On the other hand, DHA administration re-
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Figure 1. TH-immunoreactivity in the SN. (A) Control group; (B) DHA-treated group;
(C) MPTP-induced group; (D) MPTP-induced + DHA-treated group. Notice the neuronal morphological alterations;
the loss of dopaminergic neurons and the disorganized fibers in the MPTP-induced group. Scale bars = 400 µm
Figure 2. Akt immunoreactivity in the SN. (A) Control group; (B) DHA-treated group; (C) MPTP-induced group;
(D) MPTP-induced + DHA-treated group. Akt immunostaining intensities were lower in the MPTP-induced and
MPTP-induced + DHA-treated groups compared to the other two groups. Scale bars = 100 µm
A B
C D
A B
C D
233The effects of DHA in a rat model of Parkinson’s disease
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2012
10.5603/FHC.2012.0032
www.fhc.viamedica.pl
A B
C D
Figure 3. p-Akt immunoreactivity in the SN. (A) Control group; (B) DHA-treated group; (C) MPTP-induced group;
(D) MPTP-induced + DHA-treated group. A significant decrease in p-Akt immunostaining intensity in the
MPTP-induced group is seen. However it was increased in the MPTP-induced + DHA-treated group compared
to the MPTP-induced group. Scale bars = 100 µm
Figure 4. Bcl-2 immunoreactivity in the SN. (A) Control group; (B) DHA-treated group; (C) MPTP-induced group;
(D) MPTP-induced + DHA-group. The dopaminergic neurons showed weak immunostaining with Bcl-2 in the
MPTP-induced group (insets), while it was stronger in the MPTP-induced + DHA-treated group compared to the
MPTP-induced group. Please note the absence of Bcl-2 immunostaining in the negative control slide (smaller inset A).
Scale bars = 200 µm
A B
C D
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duced these symptoms in the MPTP-induced + DHA-
-treated group [33]. It has been recently demonstrated
that short-term administration of DHA reduced by
about 40% the extent of levodopa-induced dyskine-
sias in a non-human primate model of Parkinsonism
[55]. A previous study concluded that animals that re-
ceived DHA for 24 days exhibited significant reduc-
tions (47%) in the number of d-amphetamine-induced
rotations, compared to those in control rats [47].
Our results indicate that MPTP administration
leads to loss of SN dopaminergic neurons. Previous
studies have shown that MPTP caused oxidative stress
and energy crisis [56, 57]. MPTP-induced mitochon-
drial defects may play a role in the development of
apoptosis [58]. Although there is more than one path-
way to induce apoptosis, the interaction between pro-
apoptotic (Bad, Bax and Bak) and anti-apoptotic (Bcl-2
and Bcl-XL) members of the Bcl-2 family may de-
termine the fate of cells by regulating the permeabil-
ity of the mitochondrial membrane and controlling
the release of cytochrome c (cyt c) from the mito-
chondria [59, 60]. Bcl-2 is a 26-kDa protein preferen-
tially located at contact sites between the inner and
outer mitochondrial membranes [61]. Phosphoryla-
tion inactivates Bcl-2, thus promoting apoptosis, pos-
sibly by releasing Bax from Bcl-2/Bax dimers [62–64].
The Bcl-2/Bax heterodimer is the active component
for death protection [65, 66]. In response to apoptot-
ic stimulation, Bax can be released from Bcl-2/Bax
dimers and act as the channels for either ions or pro-
teins [64, 67]. This proapoptotic protein Bax forms
pores in the outer mitochondrial membrane which
help in the release of cyt c [68]. Once released to the
cytosol, cyt c could form the apoptosome together
with apoptosis-activating factor-1 (Apaf-1) and pro-
caspase-9, leading to the activation of caspase-9, and
then activation of caspase-3 [69]. Alternatively, Bcl-2
and Bcl-XL are potent antioxidants in the mitochon-
dria [70, 71].
Several studies have indicated that MPP+ toxicity
is associated with the translocation of cyt-c from the
mitochondria to the cytosol and the activation of
caspase-3 [45, 72–74]. Consistent with these observa-
tions, Bax null and Bcl-2 transgenic mice are both
resistant to MPTP neurotoxicity [19, 75, 76]. Bcl-2
overexpression has been shown to prevent cell death
[75–77], probably by inhibiting Bax translocation and
insertion into mitochondrial membrane, or via a di-
rect interaction with the channels [78]. Consistent with
that result, MPTP lesion can also increase the level
of phosphorylated Bcl-2 and decrease the interaction
of Bcl-2 with Bax. Under MPTP intoxication, Bax is
strongly upregulated in nigrostriatal dopaminergic
neurons, whereas Bcl-2 levels are decreased [79]. In
our study, Bcl-2 staining intensity was found to be de-
creased in the MPTP-induced group. This result was
consistent with previous studies [58, 80–83]. In the
present study, administration of DHA increased Bcl-2
levels in MPTP-induced + DHA-treated dopaminer-
gic neurons compared to the MPTP-induced group.
It has been demonstrated that DHA administration
correlates with an increase in Bcl-2 levels in the brain
[84, 85] and in retina tissues [84, 86]. In a cell study,
German et al. [86] found that DHA treatment induced
Bcl-2 expression in neurons. DHA protection in cells
in culture and in in vivo models may involve neuro-
protection D1 (NPD1) synthesis [87]. NPD1 is the
first identified neuroprotective DHA-derived lipid
mediator [88]. DHA plays an important role in the
pathway leading to the formation of NPD1 [88]. DHA
and NPD1 (10,17S-DHA) each showed enhanced
expression of Bcl-XL, Bcl-2 and relative downregu-
lation of Bax and Bik [84, 87] in human neural cells.
Lukiw et al. [87] concluded that in human neural cells,
DHA was used as a precursor of NPD1 biosynthesis.
Notably, during oxidative stress in human retinal cells
and ischemia/reperfusion in the brain, NPD1 elicits
neuroprotection [88, 89]. Moreover, NPD1 inhibits
IL-1 b-stimulated expression of cyclooxygenase-2
(COX-2) [84]. A further suggestion of the significance
of NPD1 in Alzheimer’s disease (AD) is the observa-
tion that hippocampal CA1 from AD patients shows
a dramatic reduction in NPD1 [87]. It has been sug-
gested that NPD1 may act at the level of signaling
that regulates promoters of the genes encoding death
repressors and effectors of the Bcl-2 family of pro-
teins [90]. In contrast, translational or posttranslation-
al events may also integrate a concerted response to
counteract oxidative stress [90]. Mukherjee et al. [90]
suggested that agents that stimulate NPD1 biosyn-
thesis, NPD1 analogs, or dietary regimens may be
useful as new preventive/therapeutic strategies for
neurodegenerative diseases.
Some studies demonstrate that the PI3K/Akt path-
way is critical for neuronal survival [91, 92]. Akt, also
known as protein kinase B (PKB), is a member of
a larger class of serine/threonine kinases. Akt has an
N-terminus pleckstrin homology domain that medi-
ates the interaction of Akt with a plasma membrane
phospholipid, phophatidylinositol 3,4,5-triphosphate
(PIP3). Extensive studies have shown that recruitment
of Akt to the plasma membrane, and its association
with PIP3, is crucial for its activation [93, 94]. Several
lines of evidence indicate that the Akt signaling path-
way responds to oxidative stress [95] and exerts a neu-
roprotective function [96, 97]. Moreover, a large num-
ber of studies in vitro have illustrated that pharmaco-
logical compounds that protect cells against oxida-
tive stress exert their neuroprotective effects through
activation of the Akt pathway [98–102].
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Activated Akt can modulate the expression of pro-
teins influencing cell death, such as inhibitors of apo-
ptosis Bcl-2 and Bcl-XL or inducers of apoptosis Bax,
Bad [103, 104]. Akt, promotes cell survival by inhibit-
ing the function of proapoptotic proteins [105]. Phos-
phorylation of the protease caspase-9 or forkhead
transcription factors by Akt blocks the induction of
apoptosis by these factors [106]. While Akt phospho-
rylation at both Ser473 and Thr308 provides maxi-
mum catalytic activity, phosphorylation at Thr308 (the
site regulated by growth factors through PI3K signal-
ing) is sufficient to activate the kinase and to main-
tain survival [107]. Dopaminergic neurons from PD
patients have greatly reduced expression of phospho-
Ser473 and –Thr308 Akt, but not of total Akt [101].
Consistent with this observation, phosphorylation of
Akt at Thr308 showed a tendency to decrease in re-
sponse to MPTP [108]. Our immunohistochemical
analysis showed a decrease in p-Akt in the MPTP-
induced group compared to the control group which
is consistent with a previous study [38]. Furthermore,
it has been demonstrated that active Akt protects ni-
gral neurons from 6-hydroxydopamine (6-OHDA)
intoxication [109].
Downstream from Akt are the prosurvival Bcl-2
and proapoptotic Bad proteins. Akt can modulate Bcl-2
family members. Akt can directly phosphorylate the
protein Bad on its serine 136, thereby inhibiting its
proapoptotic function [110]. Transcription factors
such as nuclear factor kappa-B (NF-kB) and cAMP
response element-binding (CREB) are also regulat-
ed by Akt [111, 112]; NF-kB induces expression of
the Bcl-XL and Bcl-2, and brain-derived neurotrophic
factor (BDNF) expression is up-regulated by CREB
[23, 113, 114].
It remains of clinical relevance to find active drugs
that selectively target the PI3K/Akt pathway for treat-
ment of diseases showing deregulation of Akt signal-
ing. The inhibitor of MAO-B, rasagiline, has been
found to slow the functional decline in patients with
an early, mild form of PD [26, 115]. In MPTP-treated
mice, rasagiline was shown to protect against the tox-
in, a neuroprotective effect associated with activation
of Akt [116, 117]. Our results show protection against
MPTP toxicity by DHA involving the PI3K/Akt path-
way. It has been shown that DHA activates positive
regulators of cell survival by up-regulating Akt, extra-
cellular-signal-regulated kinase (ERK) and/or Bcl-2
[85]. Besides, DHA also has a negative effect on dam-
aging factor production such as inflammatory cytok-
ines and free radicals [20, 86, 118, 119]. The mecha-
nism of activation of Akt is still controversial, even
though it has been widely investigated. It is clear that
Serine (Ser) and Threonine (Thr) phosphorylation
of Akt is required for its activation. A previous study
demonstrated that DHA induced phosphorylation of
Ser residues of Akt [20]. DHA promotes neuronal
survival by translocation/activation and phosphory-
lation of Akt [20, 120].
Although the modulatory effects of DHA on cell-
survival/cell-damaging molecules have been demon-
strated in cell studies, involvement of the inactiva-
tion of damaging mechanisms and/or the activation
of survival mechanisms in DHA-mediated PD neu-
roprotection was less known. Therefore, the present
investigation was designed to evaluate the effect of
pretreatment with DHA on experimental PD via ste-
reotactic MPTP-intoxicated animals and to attempt
to determine whether the cell-survival mechanisms
contribute to DHA’s effects. p-Akt and Bcl-2 are sur-
vival factors that can block apoptotic cell death.
In conclusion, the present study indicates that DHA
pretreatment provides protection of dopaminergic neu-
rons against MPTP-induced cell death by activating
Akt/p-Akt pathway and increasing Bcl-2 level in rats.
Increase of Bcl-2 may be due to Akt/p-Akt pathway.
The highest priority in PD research is to develop
a neuroprotective therapy to prevent, stop, or even
reverse, neurodegeneration. It may be beneficial to
investigate the neuronal protective effect of several
foods rich in DHA against PD. Additional studies are
in progress to examine the details of protective effects
of DHA for developing new therapeutic strategies.
Acknowledgements
The authors would like to thank Dr. Ramazan Demir
and Umit A. Kayisli for their kind support and Sibel
Ozer for her excellent technical assistance. This study
was partially supported by the Akdeniz University Re-
search Foundation (2004.03.0122.002), Antalya, Turkey.
References
1. Lopez GH, Ilincheta de Boschero MG, Castagnet PI, Giusto
NM. Age-associated changes in the content and fatty acid
composition of brain glycerophospholipids. Comp Biochem
Physiol B Biochem Mol Biol. 1995;112:331–343.
2. Youdim KA, Martin A, Joseph JA. Essential fatty acids and
the brain: possible health implications. Int J Dev Neurosci.
2000;18:383–399.
3. Okuyama H. Minimum requirements of n-3 and n-6 essen-
tial fatty acids for the function of the central nervous system
and for the prevention of chronic disease. Proc Soc Exp Biol
Med. 1992;200:174–176.
4. Chalon S, Delion-Vancassel S, Belzung C et al. Dietary fish
oil affects monoaminergic neurotransmission and behavior
in rats. J Nutr. 1998;128:2512–2519.
5. Kidd PM. Parkinson’s disease as multifactorial oxidative neu-
rodegeneration: implications for integrative management.
Altern Med Rev. 2000;5:502–529.
6. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K,
Seitelberger F. Brain dopamine and the syndromes of Par-
236 G Hacioglu et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2012
10.5603/FHC.2012.0032
www.fhc.viamedica.pl
kinson and Huntington. Clinical, morphological and neuro-
chemical correlations. J Neurol Sci. 1973;20:415–55.
7. Marchetti B, Serra PA, Tirolo C et al. Glucocorticoid recep-
tor-nitric oxide crosstalk and vulnerability to experimental
parkinsonism: pivotal role for glia-neuron interactions. Brain
Res Brain Res Rev. 2005;48:302–321.
8. Yuan H, Zhang ZW, Liang LW et al. Treatment strategies for
Parkinson’s disease. Neurosci Bull. 2010;26:66–76.
9. Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotrans-
mitters in Parkinson’s disease. In: Marsden CD, Fahn S, ed.
Movement Disorders 2. London: Butterworth; 1987:166–230.
10. Hartmann A, Hunot S, Michel PP et al. Caspase-3: a vulner-
ability factor and final effector in apoptotic death of dopam-
inergic neurons in Parkinson’s disease. Proc Natl Acad Sci
USA. 2000;97:2875–2880.
11. Da Cunha C, Angelucci ME, Canteras NS, Wonnacott S, Taka-
hashi RN. The lesion of the rat substantia nigra pars compacta
dopaminergic neurons as a model for Parkinson’s disease mem-
ory disabilities. Cell Mol Neurobiol. 2002;22:227–237.
12. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM,
Kopin IJ. A primate model of parkinsonism: selective de-
struction of dopaminergic neurons in the pars compacta of
the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine. Proc Natl Acad Sci USA. 1983;80:4546–4550.
13. Langston JW, Irwin I. MPTP: current concepts and contro-
versies. Clin Neuropharmacol. 1986;9:485–507.
14. Selvaraj S, Watt JA, Singh BB. TRPC1 inhibits apoptotic cell
degeneration induced by dopaminergic neurotoxin MPTP/
/MPP(+). Cell Calcium. 2009;46:209–218.
15. Chiueh CC, Markey SP, Burns RS, Johannessen JN, Jaco-
bowitz DM, Kopin IJ. Neurochemical and behavioral effects
of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in
rat, guinea pig, and monkey. Psychopharmacol Bull.
1984;20:548–553.
16. Javitch JA, D’Amato RJ, Strittmatter SM, Snyder SH. Par-
kinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-
-tetrahydropyridine: uptake of the metabolite N-methyl-4-
-phenylpyridine by dopamine neurons explains selective tox-
icity. Proc Natl Acad Sci USA. 1985;82:2173–2177.
17. Nicklas WJ, Youngster SK, Kindt MV, Heikkila RE. MPTP,
MPP+ and mitochondrial function. Life Sci. 1987;40:721–729.
18. Lotharius J, Dugan LL, O’Malley KL. Distinct mechanisms
underlie neurotoxin-mediated cell death in cultured dopam-
inergic neurons. J Neurosci. 1999;19:1284–1293.
19. Vila M, Jackson-Lewis V, Vukosavic S et al. Bax ablation pre-
vents dopaminergic neurodegeneration in the 1-methyl-4-
-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkin-
son’s disease. Proc Natl Acad Sci USA. 2001;98:2837–2842.
20. Akbar M, Calderon F, Wen Z, Kim HY. Docosahexaenoic
acid: a positive modulator of Akt signaling in neuronal sur-
vival. Proc Natl Acad Sci USA. 2005;102:10858–10863.
21. Seo JH, Rah JC, Choi SH et al. Alpha-synuclein regulates
neuronal survival via Bcl-2 family expression and PI3/Akt ki-
nase pathway. FASEB J. 2002;16:1826–1828.
22. Matsuzaki H, Tamatani M, Mitsuda N et al. Activation of
Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax
expression induced by nitric oxide in primary hippocampal
neurons. J Neurochem. 1999;73:2037–2046.
23. Pugazhenthi S, Nesterova A, Sable C et al. Akt/protein ki-
nase B up-regulates Bcl-2 expression through cAMP-response
element-binding protein. J Biol Chem. 2000;275:10761–10766.
24. Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-
-1R(+)-aminoindan], a selective and potent inhibitor of mi-
tochondrial monoamine oxidase B. Br J Pharmacol.
2001;132:500–506.
25. Parkinson Study Group. A controlled trial of rasagiline in
early Parkinson disease: the TEMPO Study. Arch Neurol.
2002;59:1937–1943.
26. Parkinson Study Group. A controlled, randomized, delayed-
start study of rasagiline in early Parkinson disease. Arch Neu-
rol. 2004;61:561–566.
27. Parkinson Study Group. A randomized placebo-controlled
trial of rasagiline in levodopa-treated patients with Parkin-
son disease and motor fluctuations: the PRESTO study. Arch
Neurol. 2005;62:241–248.
28. Hacioglu G, Agar A, Yargicoglu P. The role of docosahexaeno-
ic acid on visual evoked potentials in one kidney-one clip hy-
pertension. Acta Ophthalmol Scand. 2006;84:488–494.
29. Hacioglu G, Kose O, Aslan M, Agar A. Beneficial effects of
docosahexaenoic acid on active avoidance performance in
1K-1C hypertensive rats. Neurobiol Learn Mem. 2007;87:
159–165.
30. Kremer JM, Lawrence DA, Jubiz W et al. Dietary fish oil
and olive oil supplementation in patients with rheumatoid
arthritis. Clinical and immunologic effects. Arthritis Rheum.
1990;33:810–820.
31. Ozsoy O, Tanriover G, Derin N et al. The effect of docosa-
hexaenoic acid on visual evoked potentials in a mouse model
of Parkinson’s Disease: the role of cyclooxygenase-2 and
Nuclear Factor Kappa-B. Neurotox Res. 2011; Jan 14 [Epub
ahead of print].
32. Simopoulos AP. Summary of the NATO advanced research
workshop on dietary omega 3 and omega 6 fatty acids: bio-
logical effects and nutritional essentiality. J Nutr. 1989;119:
521–528.
33. Tanriover G, Seval-Celik Y, Ozsoy O et al. The effects of
docosahexaenoic acid on glial derived neurotrophic factor
and neurturin in bilateral rat model of Parkinson’s disease.
Folia Histochem Cytobiol. 2010;48:434–441.
34. Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci ME,
Canteras NS, Da Cunha C. Comparison of bilaterally
6-OHDA- and MPTP-lesioned rats as models of the early phase
of Parkinson’s disease: histological, neurochemical, motor and
memory alterations. J Neurosci Methods. 2005;148:78–87.
35. Pellegrino LJ, Pellegrino AS, Cushman AJ. Stereotaxic Atlas
of the Rat Brain. New York: Plenum Press; 1979.
36. Crawley J. What’s wrong with my mouse? Behavioral pheno-
typing of transgenic and knockout mice. New York: Wiley-
-Liss; 2000.
37. Papeschi R, Theiss P, Ayhan H. AMT catalepsy and hypoki-
nesia: interaction with morphine and cocaine. Psychophar-
macologia. 1976;46(2):149-57.
38. Quesada A, Lee BY, Micevych PE. PI3 kinase/Akt activation
mediates estrogen and IGF-1 nigral DA neuronal neuropro-
tection against a unilateral rat model of Parkinson’s disease.
Dev Neurobiol. 2008;68:632–644.
39. Stromberg I, Bjorklund H, Dahl D, Jonsson G, Sundstrom
E, Olson L. Astrocyte responses to dopaminergic denerva-
tions by 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-
-tetrahydropyridine as evidenced by glial fibrillary acidic pro-
tein immunohistochemistry. Brain Res Bull. 1986;17:225–236.
40. Heikkila RE, Nicklas WJ, Duvoisin RC. Dopaminergic tox-
icity after the stereotaxic administration of the 1-methyl-4-
-phenylpyridinium ion (MPP+) to rats. Neurosci Lett.
1985;59:135–140.
41. Sirinathsinghji DJ, Heavens RP, Richards SJ, Beresford IJ,
Hall MD. Experimental hemiparkinsonism in the rat follow-
ing chronic unilateral infusion of MPP+ into the nigrostriatal
dopamine pathway-I. Behavioural, neurochemical and his-
tological characterization of the lesion. Neuroscience.
1988;27:117–128.
42. Takada M, Li ZK, Hattori T. Intracerebral MPTP injections in
the rat cause cell loss in the substantia nigra, ventral tegmental
area and dorsal raphe. Neurosci Lett. 1987;78:145–150.
43. Takada M, Li ZK, Hattori T. Dopaminergic nigrotectal pro-
jection in the rat. Brain Res. 1988;457:165–168.
237The effects of DHA in a rat model of Parkinson’s disease
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2012
10.5603/FHC.2012.0032
www.fhc.viamedica.pl
44. Schober A. Classic toxin-induced animal models of Parkin-
son’s disease: 6-OHDA and MPTP. Cell Tissue Res.
2004;318:215–224.
45. Viswanath V, Wu Y, Boonplueang R, et al. Caspase-9 activa-
tion results in downstream caspase-8 activation and bid cleav-
age in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced
Parkinson’s disease. J Neurosci. 2001;21:9519–9528.
46. Bousquet M, Saint-Pierre M, Julien C, Salem N, Jr., Cicchetti F,
Calon F. Beneficial effects of dietary omega-3 polyunsaturated
fatty acid on toxin-induced neuronal degeneration in an animal
model of Parkinson’s disease. FASEB J. 2008;22:1213–1225.
47. Cansev M, Ulus IH, Wang L, Maher TJ, Wurtman RJ. Re-
storative effects of uridine plus docosahexaenoic acid in a rat
model of Parkinson’s disease. Neurosci Res. 2008;62:206–209.
48. Toit-Kohn JL, Louw L, Engelbrecht AM. Docosahexaenoic
acid induces apoptosis in colorectal carcinoma cells by mod-
ulating the PI3 kinase and p38 MAPK pathways. J Nutr Bio-
chem. 2009;20:106–114.
49. Haobam R, Sindhu KM, Chandra G, Mohanakumar KP.
Swim-test as a function of motor impairment in MPTP mod-
el of Parkinson’s disease: a comparative study in two mouse
strains. Behav Brain Res. 2005;163:159–167.
50. Capitelli C, Sereniki A, Lima MM, Reksidler AB, Tufik S,
Vital MA. Melatonin attenuates tyrosine hydroxylase loss and
hypolocomotion in MPTP-lesioned rats. Eur J Pharmacol.
2008;594:101–108.
51. Kato H, Kurosaki R, Oki C, Araki T. Arundic acid, an astro-
cyte-modulating agent, protects dopaminergic neurons against
MPTP neurotoxicity in mice. Brain Res. 2004;1030:66–73.
52. Leret ML, San Millan JA, Fabre E, Gredilla R, Barja G. De-
prenyl protects from MPTP-induced Parkinson-like syndrome
and glutathione oxidation in rat striatum. Toxicology.
2002;170:165–171.
53. Mitra N, Mohanakumar KP, Ganguly DK. Dissociation of
serotoninergic and dopaminergic components in acute effects
of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain
Res Bull. 1992;28:355–364.
54. Sedelis M, Schwarting RK, Huston JP. Behavioral phenotyp-
ing of the MPTP mouse model of Parkinson’s disease. Behav
Brain Res. 2001;125:109–125.
55. Samadi P, Gregoire L, Rouillard C, Bedard PJ, Di Paolo T,
Levesque D. Docosahexaenoic acid reduces levodopa-in-
duced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropy-
ridine monkeys. Ann Neurol. 2006;59:282–288.
56. Abdulwahid Arif I, Ahmad Khan H. Environmental toxins
and Parkinson’s disease: putative roles of impaired electron
transport chain and oxidative stress. Toxicol Ind Health.
2010;26:121–128.
57. Mizuno Y, Suzuki K, Sone N, Saitoh T. Inhibition of ATP
synthesis by 1-methyl-4-phenylpyridinium ion (MPP+) in iso-
lated mitochondria from mouse brains. Neurosci Lett.
1987;81:204–208.
58. Mills RD, Sim CH, Mok SS, Mulhern TD, Culvenor JG,
Cheng HC. Biochemical aspects of the neuroprotective mech-
anism of PTEN-induced kinase-1 (PINK1). J Neurochem.
2008;105:18–33.
59. Crompton M. Bax, Bid and the permeabilization of the mito-
chondrial outer membrane in apoptosis. Curr Opin Cell Biol.
2000;12:414–419.
60. Lee DH, Szczepanski M, Lee YJ. Role of Bax in quercetin-
induced apoptosis in human prostate cancer cells. Biochem
Pharmacol. 2008;75:2345–2355.
61. Reed JC. Double identity for proteins of the Bcl-2 family.
Nature. 1997;387:773–776.
62. Biswas SC, Shi Y, Sproul A, Greene LA. Pro-apoptotic Bim
induction in response to nerve growth factor deprivation re-
quires simultaneous activation of three different death sig-
naling pathways. J Biol Chem. 2007;282:29368–29374.
63. Liu XM, Pei DS, Guan QH et al. Neuroprotection of Tat-
GluR6-9c against neuronal death induced by kainate in rat
hippocampus via nuclear and non-nuclear pathways. J Biol
Chem. 2006;281:17432–17445.
64. Pei DS, Wang XT, Liu Y et al. Neuroprotection against is-
chaemic brain injury by a GluR6-9c peptide containing the
TAT protein transduction sequence. Brain. 2006;129:465–479.
65. Rezende AC, Vieira AS, Rogerio F et al. Effects of systemic
administration of ciliary neurotrophic factor on Bax and Bcl-2
proteins in the lumbar spinal cord of neonatal rats after sciatic
nerve transection. Braz J Med Biol Res. 2008;41:1024–1028.
66. Zhang Z, Lapolla SM, Annis MG et al. Bcl-2 homodimeriza-
tion involves two distinct binding surfaces, a topographic ar-
rangement that provides an effective mechanism for Bcl-2 to
capture activated Bax. J Biol Chem. 2004;279:43920–43928.
67. Patel JR, Brewer GJ. Age-related differences in NFkappaB
translocation and Bcl-2/Bax ratio caused by TNFalpha and
Abeta42 promote survival in middle-age neurons and death
in old neurons. Exp Neurol. 2008;213:93–100.
68. Mohan J, Gandhi AA, Bhavya BC et al. Caspase-2 triggers
Bax-Bak-dependent and -independent cell death in colon
cancer cells treated with resveratrol. J Biol Chem.
2006;281:17599–17611.
69. Thornberry NA, Lazebnik Y. Caspases: enemies within. Sci-
ence. 1998;281:1312–1316.
70. Fennell DA, Corbo M, Pallaska A, Cotter FE. Bcl-2 resistant
mitochondrial toxicity mediated by the isoquinoline carboxa-
mide PK11195 involves de novo generation of reactive oxy-
gen species. Br J Cancer. 2001;84:1397–1404.
71. Kowaltowski AJ, Fenton RG, Fiskum G. Bcl-2 family pro-
teins regulate mitochondrial reactive oxygen production and
protect against oxidative stress. Free Radic Biol Med.
2004;37:1845–1853.
72. Blum D, Torch S, Lambeng N et al. Molecular pathways in-
volved in the neurotoxicity of 6-OHDA, dopamine and MPTP:
contribution to the apoptotic theory in Parkinson’s disease.
Prog Neurobiol. 2001;65:135–172.
73. Cassarino DS, Parks JK, Parker WD, Jr., Bennett JP, Jr. The
parkinsonian neurotoxin MPP+ opens the mitochondrial per-
meability transition pore and releases cytochrome c in iso-
lated mitochondria via an oxidative mechanism. Biochim Bio-
phys Acta. 1999;1453:49–62.
74. Chinnaiyan AM, Orth K, O’Rourke K, Duan H, Poirier GG,
Dixit VM. Molecular ordering of the cell death pathway. Bcl-
2 and Bcl-xL function upstream of the CED-3-like apoptotic
proteases. J Biol Chem. 1996;271:4573–4576.
75. Offen D, Beart PM, Cheung NS et al. Transgenic mice ex-
pressing human Bcl-2 in their neurons are resistant to 6-hy-
droxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropy-
ridine neurotoxicity. Proc Natl Acad Sci USA. 1998;95:5789–
5794.
76. Yang L, Matthews RT, Schulz JB et al. 1-Methyl-4-phenyl-
1,2,3,6-tetrahydropyride neurotoxicity is attenuated in mice
overexpressing Bcl-2. J Neurosci. 1998;18:8145–8152.
77. O’Malley KL, Liu J, Lotharius J, Holtz W. Targeted expres-
sion of BCL-2 attenuates MPP+ but not 6-OHDA induced
cell death in dopaminergic neurons. Neurobiol Dis.
2003;14:43–51.
78. Cheng EH, Wei MC, Weiler S, et al. BCL-2, BCL-X(L) se-
quester BH3 domain-only molecules preventing BAX- and
BAK-mediated mitochondrial apoptosis. Mol Cell.
2001;8:705–711.
79. Youdim MB, Arraf Z. Prevention of MPTP (N-methyl-4-phe-
nyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in
mice by chronic lithium: involvements of Bcl-2 and Bax. Neu-
ropharmacology. 2004;46:1130–1140.
80. Dauer W, Przedborski S. Parkinson’s disease: mechanisms
and models. Neuron. 2003;39:889–909.
238 G Hacioglu et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2012
10.5603/FHC.2012.0032
www.fhc.viamedica.pl
81. Jiang H, Li LJ, Wang J, Xie JX. Ghrelin antagonizes MPTP-
-induced neurotoxicity to the dopaminergic neurons in mouse
substantia nigra. Exp Neurol. 2008;212:532–537.
82. Jung HW, Son HY, Jin GZ, Park YK. Preventive role of PD-1
on MPTP-induced dopamine depletion in mice. Cell Biochem
Funct. 2010;28:217–223.
83. Shin JY, Park HJ, Ahn YH, Lee PH. Neuroprotective effect of
L-dopa on dopaminergic neurons is comparable to pramipex-
ol in MPTP-treated animal model of Parkinson’s disease:
a direct comparison study. J Neurochem. 2009;111:1042-1050.
84. Bazan NG. Cellular and molecular events mediated by
docosahexaenoic acid-derived neuroprotectin D1 signaling
in photoreceptor cell survival and brain protection. Prostag-
landins Leukot Essent Fatty Acids. 2009;81:205–211.
85. Pan HC, Kao TK, Ou YC et al. Protective effect of docosa-
hexaenoic acid against brain injury in ischemic rats. J Nutr
Biochem. 2009;20:715–725.
86. German OL, Insua MF, Gentili C, Rotstein NP, Politi LE.
Docosahexaenoic acid prevents apoptosis of retina photore-
ceptors by activating the ERK/MAPK pathway. J Neurochem.
2006;98:1507–1520.
87. Lukiw WJ, Cui JG, Marcheselli VL et al. A role for docosa-
hexaenoic acid-derived neuroprotectin D1 in neural cell sur-
vival and Alzheimer disease. J Clin Invest. 2005;115:2774–2783.
88. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG.
Neuroprotectin D1: a docosahexaenoic acid-derived docosa-
triene protects human retinal pigment epithelial cells from
oxidative stress. Proc Natl Acad Sci USA. 2004;101:8491–8496.
89. Marcheselli VL, Hong S, Lukiw WJ et al. Novel docosanoids
inhibit brain ischemia-reperfusion-mediated leukocyte infil-
tration and pro-inflammatory gene expression. J Biol Chem.
2003;278:43807–43817.
90. Mukherjee PK, Chawla A, Loayza MS, Bazan NG.
Docosanoids are multifunctional regulators of neural cell in-
tegrity and fate: significance in aging and disease. Prostaglan-
dins Leukot Essent Fatty Acids. 2007;77:233–238.
91. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream
AKTion blocks apoptosis. Cell. 1997;88:435–437.
92. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regula-
tion of the Akt proto-oncogene product by phosphatidylinos-
itol-3,4-bisphosphate. Science. 1997;275:665–668.
93. Klippel A, Kavanaugh WM, Pot D, Williams LT. A specific
product of phosphatidylinositol 3-kinase directly activates the
protein kinase Akt through its pleckstrin homology domain.
Mol Cell Biol. 1997;17:338–344.
94. Kohn AD, Takeuchi F, Roth RA. Akt, a pleckstrin homology
domain containing kinase, is activated primarily by phospho-
rylation. J Biol Chem. 1996;271:21920–21926.
95. Crossthwaite AJ, Hasan S, Williams RJ. Hydrogen peroxide-
mediated phosphorylation of ERK1/2, Akt/PKB and JNK in
cortical neurones: dependence on Ca(2+) and PI3-kinase.
J Neurochem. 2002;80:24–35.
96. Lee HJ, Kim MK, Kim HJ, Kim SU. Human neural stem
cells genetically modified to overexpress Akt1 provide neu-
roprotection and functional improvement in mouse stroke
model. PLoS One. 2009;4:e5586.
97. Sun X, Yao H, Douglas RM, Gu XQ, Wang J, Haddad GG.
Insulin/PI3K signaling protects dentate neurons from oxy-
gen-glucose deprivation in organotypic slice cultures. J Neu-
rochem. 2010;112:377–388.
98. Dudek H, Datta SR, Franke TF et al. Regulation of neu-
ronal survival by the serine-threonine protein kinase Akt.
Science. 1997;275:661–665.
99. Heo SR, Han AM, Kwon YK, Joung I. p62 protects SH-SY5Y
neuroblastoma cells against H2O2-induced injury through the
PDK1/Akt pathway. Neurosci Lett. 2009;450:45–50.
100. Liu JH, Yin F, Guo LX, Deng XH, Hu YH. Neuroprotection
of geniposide against hydrogen peroxide induced PC12 cells
injury: involvement of PI3 kinase signal pathway. Acta Phar-
macol Sin. 2009;30:159–165.
101. Malagelada C, Jin ZH, Greene LA. RTP801 is induced in
Parkinson’s disease and mediates neuron death by inhibiting Akt
phosphorylation/activation. J Neurosci. 2008;28:14363–14371.
102. Li Z, Hu Y, Zhu Q, Zhu J. Neurotrophin-3 reduces apopto-
sis induced by 6-OHDA in PC12 cells through Akt signaling
pathway. Int J Dev Neurosci. 2008;26:635–640.
103. Garcia-Segura LM, Azcoitia I, DonCarlos LL. Neuroprotec-
tion by estradiol. Prog Neurobiol. 2001;63:29–60.
104. Mattson MP. Apoptosis in neurodegenerative disorders. Nat
Rev Mol Cell Biol. 2000;1:120–129.
105. Manning BD, Cantley LC. AKT/PKB signaling: navigating
downstream. Cell. 2007;129:1261–1274.
106. Brunet A, Bonni A, Zigmond MJ et al. Akt promotes cell
survival by phosphorylating and inhibiting a Forkhead tran-
scription factor. Cell. 1999;96:857–868.
107. Jacinto E, Facchinetti V, Liu D et al. SIN1/MIP1 maintains
rictor-mTOR complex integrity and regulates Akt phospho-
rylation and substrate specificity. Cell. 2006;127:125–137.
108. Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S,
Greene LA. Rapamycin protects against neuron death in in
vitro and in vivo models of Parkinson’s disease. J Neurosci.
2010;30:1166–1175.
109. Ries V, Henchcliffe C, Kareva T et al. Oncoprotein Akt/PKB
induces trophic effects in murine models of Parkinson’s dis-
ease. Proc Natl Acad Sci USA. 2006;103:18757–18762.
110. Datta SR, Dudek H, Tao X et al. Akt phosphorylation of
BAD couples survival signals to the cell-intrinsic death ma-
chinery. Cell. 1997;91:231–241.
111. Du K, Montminy M. CREB is a regulatory target for the pro-
tein kinase Akt/PKB. J Biol Chem. 1998;273:32377–32379.
112. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT
in anti-apoptotic PDGF signalling. Nature. 1999;401:86–90.
113. Brunet A, Datta SR, Greenberg ME. Transcription-depen-
dent and -independent control of neuronal survival by the
PI3K-Akt signaling pathway. Curr Opin Neurobiol. 2001;
11:297–305.
114, Finkbeiner S, Tavazoie SF, Maloratsky A, Jacobs KM, Harris KM,
Greenberg ME. CREB: a major mediator of neuronal neuro-
trophin responses. Neuron. 1997;19:1031–1047.
115. Blandini F. Neuroprotection by rasagiline: a new therapeutic
approach to Parkinson’s disease? CNS Drug Rev. 2005;11:
183–194.
116. Mandel SA, Sagi Y, Amit T. Rasagiline promotes regenera-
tion of substantia nigra dopaminergic neurons in post-MPTP-
-induced Parkinsonism via activation of tyrosine kinase re-
ceptor signaling pathway. Neurochem Res. 2007;32:1694–1699.
117. Sagi Y, Mandel S, Amit T, Youdim MB. Activation of tyrosine
kinase receptor signaling pathway by rasagiline facilitates
neurorescue and restoration of nigrostriatal dopamine neu-
rons in post-MPTP-induced parkinsonism. Neurobiol Dis.
2007;25:35-44.
118. Chen W, Esselman WJ, Jump DB, Busik JV. Anti-inflamma-
tory effect of docosahexaenoic acid on cytokine-induced ad-
hesion molecule expression in human retinal vascular endot-
helial cells. Invest Ophthalmol Vis Sci. 2005;46:4342–4347.
119. Florent S, Malaplate-Armand C, Youssef I et al. Docosa-
hexaenoic acid prevents neuronal apoptosis induced by solu-
ble amyloid-beta oligomers. J Neurochem. 2006;96:385–395.
120. Lee JY, Ye J, Gao Z et al. Reciprocal modulation of Toll-like
receptor-4 signaling pathways involving MyD88 and phos-
phatidylinositol 3-kinase/AKT by saturated and polyunsatu-
rated fatty acids. J Biol Chem. 2003;278:37041–37051.
Submitted: 30 March, 2011
Accepted after reviews: 27 June, 2011
